Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves...

Area of Science:

• Clinical Microbiology
• Infectious Diseases
• Molecular Diagnostics

Background:

• Timely and accurate microbiological diagnosis is crucial for effective antimicrobial therapy in community-acquired pneumonia (CAP).
• Current standard diagnostic methods often lack the speed and comprehensiveness needed for prompt treatment decisions.

Purpose of the Study:

• To evaluate the real-world performance of the BioFire FilmArray Pneumonia panel plus (FAP plus) for diagnosing CAP.
• To assess the feasibility of using this molecular panel in a randomized controlled trial setting.

Main Methods:

• A prospective feasibility study involving patients with suspected CAP.
• Comparison of FAP plus turnaround time (TAT) and microbiological yield against standard diagnostic methods (SDs), including in-house PCR and sputum cultures.
• Analysis of respiratory tract samples (induced sputum or endotracheal aspirate).

Main Results:

• The FAP plus demonstrated a significantly shorter median TAT compared to in-house PCR (2.6 vs 24.1 hours) and sputum cultures (2.6 vs 57.5 hours).
• The overall microbiological yield of FAP plus was substantially higher (91%) than SDs (55%).
• Commonly identified pathogens included Haemophilus influenzae, Streptococcus pneumoniae, and influenza A virus.

Conclusions:

• Molecular panel testing, such as FAP plus, significantly reduces time to actionable results in adult CAP patients.
• The FAP plus offers an increased microbiological yield, aiding in more precise diagnosis.
• Further randomized controlled trials are warranted to evaluate the impact of this molecular panel on antibiotic use and patient outcomes.